Genmab A/S
GMAB
View Detailed Chart
33.420USD
-0.300-0.89%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
20.58BMarket Cap
14.14P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.89%
5 Days
+3.21%
1 Month
+4.70%
6 Months
+61.22%
Year to Date
+60.13%
1 Year
+62.39%
View Detailed Chart
TradingKey Stock Score of Genmab A/S
Currency: USD Updated: 2025-12-26Key Insights
Genmab A/S's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 12/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.02.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Genmab A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
36.022
Target Price
+12.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Genmab A/S Highlights
StrengthsRisks
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 51.10% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.12B.
Overvalued
The company’s latest PE is 14.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 64.81M shares, decreasing 19.49% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 1.96K shares of this stock.
Genmab A/S News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Genmab A/S Info
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Ticker SymbolGMAB
CompanyGenmab A/S
CEOVan De Winkel (Jan G.J)
Websitehttps://www.genmab.com/
FAQs
What is the current price of Genmab A/S (GMAB)?
The current price of Genmab A/S (GMAB) is 33.420.
What is the symbol of Genmab A/S?
The ticker symbol of Genmab A/S is GMAB.
What is the 52-week high of Genmab A/S?
The 52-week high of Genmab A/S is 33.890.
What is the 52-week low of Genmab A/S?
The 52-week low of Genmab A/S is 17.235.
What is the market capitalization of Genmab A/S?
The market capitalization of Genmab A/S is 20.58B.
What is the net income of Genmab A/S?
The net income of Genmab A/S is 1.14B.
Is Genmab A/S (GMAB) currently rated as Buy, Hold, or Sell?
According to analysts, Genmab A/S (GMAB) has an overall rating of Buy, with a price target of 36.022.
What is the Earnings Per Share (EPS TTM) of Genmab A/S (GMAB)?
The Earnings Per Share (EPS TTM) of Genmab A/S (GMAB) is 2.364.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
